Catestatin
- Category
- Cardiovascular
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A chromogranin A fragment from nerve endings and adrenal glands, marketed for blood pressure, heart, and gut support. Evidence is mostly animal and mechanistic; in humans it is studied mainly as a heart failure biomarker, while hypertension and colitis claims stay low confidence. Therapeutic safety remains unestablished, and suppressing adrenaline raises concern for hypotension and allergy. Not approved, and available products are unregulated.
Read Full recordStudied uses & evidence
Studied uses(7)
Blood pressure regulation and antihypertensive effects
LowAnimal evidence and limited human vascular experiments; antihypertensive treatment benefit remains unproven.
Cardioprotection against ischemia-reperfusion injury
LowReduced infarct size in rodent heart studies via defined signaling pathways; no human data exist.
Improved insulin sensitivity and metabolic function
LowImproved insulin sensitivity in mouse and rat studies only; human data are limited to associations.
Evidence limits
- Evidence Level
- Preclinical
Therapeutic evidence remains predominantly preclinical, from in vitro cell culture and in vivo animal (primarily mouse) studies. Human research includes observational biomarker studies, population genetics, and controlled local-infusion experiments. The CATSTAT-HF study (NCT03389386), the largest dedicated clinical study, measured endogenous catestatin in 90 acutely decompensated heart failure patients. Population genetics studies in Indian cohorts (approximately 4,000 subjects) linked catestatin variants to hypertension risk. These findings do not establish clinical treatment benefit. The preclinical evidence across cardiovascular, metabolic, inflammatory, and antimicrobial domains is consistent and compelling, but clinical translation has not yet begun.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Severe hypotension
HighCatestatin inhibits catecholamine release and causes vasodilation. May dangerously lower BP in hypotensive patients.
Pheochromocytoma or catecholamine-secreting tumors
ModerateCatestatin modulates catecholamine dynamics. Unpredictable effects on catecholamine-secreting tumors.
General cautions
Pregnancy
AbsoluteNo reproductive safety data. Affects catecholamine and cardiovascular regulation.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
Therapeutic safety remains unestablished
HighHypotension and cardiovascular depression
ModerateHistamine release and allergic-type reactions
ModerateImmune modulation with unpredictable consequences
ModerateSympathetic rebound or autonomic instability
TheoreticalResearch-grade product quality and contamination
HighVariant-specific differential effects
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.